Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Journal of Hematology & Oncology
|
August 17, 2016
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu, Jie Sun, Zhao Wu, et al.
Cancer Research and Treatment
|
February 6, 2018
Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
Yongxian Hu, Jiasheng Wang, Chengfei Pu, et al.
BMC Cancer
|
February 21, 2022
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis
Xiaowei Zhang, Yuchen Wu, Xuefei Sun, et al.
Annals of Hematology
|
February 9, 2018
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
Guoqing Wei, Yongxian Hu, Chengfei Pu, et al.
Frontiers in Neurology
|
June 20, 2025
Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
Yuchen Wu, Xuefei Sun, Liwei Lv, et al.
BMC Neurology
|
November 6, 2019
Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population
Yuchen Wu, Yaming Wang, Xuefei Sun, et al.
Chinese Neurosurgical Journal
|
April 2, 2021
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study
Yuchen Wu, Xuefei Sun, Xueyan Bai, et al.
Frontiers in Oncology
|
March 14, 2022
Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
Xuefei Sun, Yuchen Wu, Ruixian Xing, et al.
Brain and Behavior
|
June 14, 2020
Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors
Na Shen, Yaming Wang, Xuefei Sun, et al.
International Journal of Hematology
|
June 24, 2011
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells
Qu Cui, Hironobu Shibata, Asuka Oda, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Journal of Hematology & Oncology
|
August 17, 2016
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu, Jie Sun, Zhao Wu, et al.
Cancer Research and Treatment
|
February 6, 2018
Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
Yongxian Hu, Jiasheng Wang, Chengfei Pu, et al.
BMC Cancer
|
February 21, 2022
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis
Xiaowei Zhang, Yuchen Wu, Xuefei Sun, et al.
Annals of Hematology
|
February 9, 2018
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
Guoqing Wei, Yongxian Hu, Chengfei Pu, et al.
Frontiers in Neurology
|
June 20, 2025
Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
Yuchen Wu, Xuefei Sun, Liwei Lv, et al.
BMC Neurology
|
November 6, 2019
Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population
Yuchen Wu, Yaming Wang, Xuefei Sun, et al.
Chinese Neurosurgical Journal
|
April 2, 2021
Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study
Yuchen Wu, Xuefei Sun, Xueyan Bai, et al.
Frontiers in Oncology
|
March 14, 2022
Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
Xuefei Sun, Yuchen Wu, Ruixian Xing, et al.
Brain and Behavior
|
June 14, 2020
Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors
Na Shen, Yaming Wang, Xuefei Sun, et al.
International Journal of Hematology
|
June 24, 2011
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells
Qu Cui, Hironobu Shibata, Asuka Oda, et al.
Page
of 5